Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study
Background No study has focused on the economic burden in non‐Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long‐term NHL survivors. Meth...
Uloženo v:
| Vydáno v: | Cancer Ročník 128; číslo 3; s. 519 - 528 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Wiley
01.02.2022
Wiley Subscription Services, Inc |
| Témata: | |
| ISSN: | 0008-543X, 1097-0142, 1097-0142 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
No study has focused on the economic burden in non‐Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long‐term NHL survivors.
Methods
Health care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs.
Results
In total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs.
Conclusions
The consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design person‐centered health care pathways.
Improvements in the management of non‐Hodgkin lymphoma (NHL) have led to longer survival with potentially increased health care consumption and costs. This cross‐sectional study in long‐term NHL survivors shows that health care resource use and associated costs are linked to sociodemographic factors and comorbidities with no influence from previous lymphoma treatments (chemotherapy, rituximab, and transplantation). |
|---|---|
| AbstractList | BackgroundNo study has focused on the economic burden in non‐Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long‐term NHL survivors.MethodsHealth care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs.ResultsIn total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs.ConclusionsThe consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design person‐centered health care pathways. No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long-term NHL survivors. METHODS: Health care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs. RESULTS: In total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs. CONCLUSIONS: The consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design personcentered health care pathways. No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long-term NHL survivors.BACKGROUNDNo study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long-term NHL survivors.Health care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs.METHODSHealth care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs.In total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs.RESULTSIn total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs.The consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design person-centered health care pathways.CONCLUSIONSThe consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design person-centered health care pathways. Background No study has focused on the economic burden in non‐Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long‐term NHL survivors. Methods Health care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs. Results In total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs. Conclusions The consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design person‐centered health care pathways. Improvements in the management of non‐Hodgkin lymphoma (NHL) have led to longer survival with potentially increased health care consumption and costs. This cross‐sectional study in long‐term NHL survivors shows that health care resource use and associated costs are linked to sociodemographic factors and comorbidities with no influence from previous lymphoma treatments (chemotherapy, rituximab, and transplantation). Improvements in the management of non‐Hodgkin lymphoma (NHL) have led to longer survival with potentially increased health care consumption and costs. This cross‐sectional study in long‐term NHL survivors shows that health care resource use and associated costs are linked to sociodemographic factors and comorbidities with no influence from previous lymphoma treatments (chemotherapy, rituximab, and transplantation). No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long-term NHL survivors. Health care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs. In total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs. The consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design person-centered health care pathways. |
| Author | Virginie Nerich Gandhi L. Damaj Jean‐Philippe Jais Catherine Thieblemont René‐Olivier Casasnovas Christophe Guyeux Hervé Tilly Corinne Haioun Emmanuelle Nicolas‐Virelizier Gilles Salles Raphaël Couturier Florence Broussais‐Guillaumot Loic Ysebaert Vincent Ribrag Macha Woronoff‐Lemsi Nicolas Mounier Franck Morschhauser David Sibon Pierre Feugier Michel Henry‐Amar |
| Author_xml | – sequence: 1 givenname: Virginie orcidid: 0000-0002-0351-6040 surname: Nerich fullname: Nerich, Virginie organization: Department of Pharmacy University Hospital Besançon France, INSERM, EFS‐BFC, UMR1098 University of Franche‐Comté Besançon France – sequence: 2 givenname: Christophe surname: Guyeux fullname: Guyeux, Christophe organization: Femto‐ST Institute, UMR 6174 CNRS, University of Bourgogne Franche‐Comté Besançon France – sequence: 3 givenname: Michel orcidid: 0000-0002-9357-6476 surname: Henry‐Amar fullname: Henry‐Amar, Michel organization: French Center on eHealth, North‐West Region Data Processing Center and French National League Against Cancer Clinical Research Platform CCC François Baclesse Caen France – sequence: 4 givenname: Raphaël surname: Couturier fullname: Couturier, Raphaël organization: Femto‐ST Institute, UMR 6174 CNRS, University of Bourgogne Franche‐Comté Besançon France – sequence: 5 givenname: Catherine surname: Thieblemont fullname: Thieblemont, Catherine organization: Hemato‐Oncology Unit Saint‐Louis University Hospital Center Public Hospital Network of Paris Paris France – sequence: 6 givenname: Vincent surname: Ribrag fullname: Ribrag, Vincent organization: Hematology Unit Gustave Roussy Cancer Campus Villejuif France – sequence: 7 givenname: Hervé surname: Tilly fullname: Tilly, Hervé organization: Hematology Department and French Institute of Health and Medical Research Unit 1243 Henri Becquerel Center Rouen France – sequence: 8 givenname: Corinne surname: Haioun fullname: Haioun, Corinne organization: Lymphoid Malignancies Unit Henri Mondor University Hospital Center Public Hospital Network of Paris Créteil France – sequence: 9 givenname: René‐Olivier surname: Casasnovas fullname: Casasnovas, René‐Olivier organization: Hematology Unit and French Institute of Health and Medical Research Unit 1231 Bocage Hospital Dijon Bourgogne Regional University Hospital Center Dijon France – sequence: 10 givenname: Franck surname: Morschhauser fullname: Morschhauser, Franck organization: Hematology Transfusion Institute Claude Huriez Hospital Lille Regional University Hospital Center Lille France – sequence: 11 givenname: Pierre surname: Feugier fullname: Feugier, Pierre organization: Hematology Unit Brabois Hospital Nancy University Hospital Center Vandoeuvre‐lès‐Nancy France – sequence: 12 givenname: David surname: Sibon fullname: Sibon, David organization: Hematology Unit Necker University Hospital for Sick Children Public Hospital Network of Paris Paris France – sequence: 13 givenname: Loic orcidid: 0000-0003-4102-7261 surname: Ysebaert fullname: Ysebaert, Loic organization: Oncopole Toulouse University Cancer Institute Toulouse France – sequence: 14 givenname: Emmanuelle surname: Nicolas‐Virelizier fullname: Nicolas‐Virelizier, Emmanuelle organization: Hematology Unit Léon Bérard Center Lyon France – sequence: 15 givenname: Florence surname: Broussais‐Guillaumot fullname: Broussais‐Guillaumot, Florence organization: Clinical Research Department–Lymphoma Study Association Lyon South Hospital Center Pierre‐Bénite France – sequence: 16 givenname: Gandhi L. surname: Damaj fullname: Damaj, Gandhi L. organization: Basse‐Normandy Hematology Institute Côte de Nacre Regional University Hospital Center Caen France – sequence: 17 givenname: Jean‐Philippe surname: Jais fullname: Jais, Jean‐Philippe organization: Laboratory of Biostatistics Paris V University–Descartes Paris France – sequence: 18 givenname: Gilles orcidid: 0000-0002-9541-8666 surname: Salles fullname: Salles, Gilles organization: Faculty of Medicine Claude Bernard University Lyon France, Hematology Department Lyon South Hospital Center Pierre‐Bénite France – sequence: 19 givenname: Macha surname: Woronoff‐Lemsi fullname: Woronoff‐Lemsi, Macha organization: INSERM, EFS‐BFC, UMR1098 University of Franche‐Comté Besançon France, Department of Clinical Research and Innovation University Hospital Besançon France – sequence: 20 givenname: Nicolas surname: Mounier fullname: Mounier, Nicolas organization: Onco‐Hematology Unit l'Archet Hospital Nice University Hospital Center University of Côte d'Azur Nice France |
| BackLink | https://cir.nii.ac.jp/crid/1870020692704294912$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/34605020$$D View this record in MEDLINE/PubMed https://hal.science/hal-03692839$$DView record in HAL |
| BookMark | eNp9kc1u1DAUhS1URIfSDQ-ALMECkFL8k8Qxu9GoZSqFVqKzYGc5jsMYEntqJ1NNVzwCz8iT4Ew6LCrExpavv3Oufc9zcGSd1QC8xOgMI0Q-KKv8GaWcFk_ADCPOEoRTcgRmCKEiyVL69RichmCqCOc5yzh9Bo5pmqMMETQD9-fKWdcZBavB19pCY2Hs8Pvnr6Wrv_2Ip3bXbdaukzAMfmu2zoePcLXW8MJrq9awPFzf9EO9g_MQnDKyN87Cm8vP11fzEirvQoiOQauxLlsYRvYFeNrINujTh_0ErC7OV4tlUl5_ulzMy0RlhBRJrlmBs4JVWZVTjBtM65pKrlNU0BGQvCkU5UhRrZqUNI2ihBFS6bShmeb0BLybbNeyFRtvOul3wkkjlvNSjDVEc04Kyrc4sm8nduPd7aBDLzoTlG5babUbgiAZ44hjyrKIvn6EfneDj5-LVE4wwQynY_NXD9RQdbr-2_8QQATQBOyH5HUjlOn34-u9NK3ASIwxizFmsY85St4_khxc_wnjCb4zrd79hxSLq8WXg-bNpLHGxOeMKy5YxFEcFEMp4SnHhP4B2-7Ctw |
| CitedBy_id | crossref_primary_10_1007_s40274_021_08101_2 crossref_primary_10_1007_s00277_025_06261_w |
| Cites_doi | 10.1016/j.surg.2019.09.010 10.1001/jamaoto.2018.3982 10.1080/13696998.2016.1187622 10.3390/ijerph14030308 10.1016/S1470-2045(17)30444-8 10.1080/10428190600573325 10.1155/2012/978391 10.1007/s00277-018-3501-8 10.2217/fon-2018-0267 10.31557/APJCP.2019.20.7.2131 10.1016/S0167-6296(01)00086-8 10.1097/MLR.0000000000000486 10.1038/nrclinonc.2016.205 10.1080/10428194.2019.1648804 10.1080/14737167.2019.1680288 10.2165/11314820-000000000-00000 10.3109/10428194.2011.592623 10.1007/s10147-017-1202-2 10.3324/haematol.2010.038109 10.1002/cncr.32040 10.1002/onco.13721 10.1080/10428194.2017.1375100 |
| ContentType | Journal Article |
| Contributor | Université Bourgogne Franche-Comté COMUE (UBFC) Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon) Franche-Comté Électronique Mécanique, Thermique et Optique - Sciences et Technologies (UMR 6174) (FEMTO-ST) Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC) Université Claude Bernard Lyon 1 (UCBL) Centre Hospitalier Régional Universitaire Lille (CHRU Lille) Centre Hospitalier Régional Universitaire [CHU Lille] (CHRU Lille) Université de Franche-Comté (UFC) Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC) Université de Lyon Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille) Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon Franche-Comté Électronique Mécanique, Thermique et Optique - Sciences et Technologies (UMR 6174) (FEMTO-ST) ; Université de Technolo |
| Contributor_xml | – sequence: 1 fullname: Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon) – sequence: 2 fullname: Franche-Comté Électronique Mécanique, Thermique et Optique - Sciences et Technologies (UMR 6174) (FEMTO-ST) ; Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC) ; Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC) – sequence: 3 fullname: Centre Hospitalier Régional Universitaire [CHU Lille] (CHRU Lille) – sequence: 4 fullname: Université Claude Bernard Lyon 1 (UCBL) ; Université de Lyon – sequence: 5 fullname: Université de Franche-Comté (UFC) ; Université Bourgogne Franche-Comté [COMUE] (UBFC) – sequence: 6 fullname: Centre Hospitalier Régional Universitaire [CHU Lille] (CHRU Lille) ; Université de Lille – sequence: 7 fullname: Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille) – sequence: 8 fullname: Franche-Comté Électronique Mécanique, Thermique et Optique - Sciences et Technologies (UMR 6174) (FEMTO-ST) – sequence: 9 fullname: Université de Technologie de Belfort-Montbeliard (UTBM)-Ecole Nationale Supérieure de Mécanique et des Microtechniques (ENSMM)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC) – sequence: 10 fullname: Université Bourgogne Franche-Comté COMUE (UBFC)-Université Bourgogne Franche-Comté COMUE (UBFC) – sequence: 11 fullname: Centre Hospitalier Régional Universitaire Lille (CHRU Lille) – sequence: 12 fullname: Université Claude Bernard Lyon 1 (UCBL) – sequence: 13 fullname: Université de Lyon – sequence: 14 fullname: Université de Franche-Comté (UFC) – sequence: 15 fullname: Université Bourgogne Franche-Comté COMUE (UBFC) |
| Copyright | 2021 American Cancer Society 2021 American Cancer Society. 2022 American Cancer Society Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2021 American Cancer Society – notice: 2021 American Cancer Society. – notice: 2022 American Cancer Society – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 1XC |
| DOI | 10.1002/cncr.33938 |
| DatabaseName | CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Economics Computer Science |
| EISSN | 1097-0142 |
| EndPage | 528 |
| ExternalDocumentID | oai:HAL:hal-03692839v1 34605020 10_1002_cncr_33938 CNCR33938 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Ligue Contre le Cancer – fundername: Agence Nationale de Sécurité du Médicament et des Produits de Santé funderid: AAP‐2012‐20 – fundername: Agence Nationale de Sécurité du Médicament et des Produits de Santé grantid: AAP-2012-20 |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1CY 1L6 1OC 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RX1 RYH RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT 24P AAHHS AARRQ ADZOD AEUQT AFPWT RWI WRC .GJ .Y3 31~ 3O- AAQOH AAYXX AFFNX AGNAY AI. C1A CITATION EJD HF~ H~9 J5H LW6 N4W NEJ O8X OHT RSU VH1 WHG Y6R YQJ ZXP CGR CUY CVF ECM EIF NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 1XC |
| ID | FETCH-LOGICAL-c5228-6e781587b5b6311f13dd3a9e40835228a9f8c390c3ecf42ffc32722be4f35e93 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000703020300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Sat Nov 29 15:04:01 EST 2025 Sun Sep 28 02:35:17 EDT 2025 Sat Nov 29 14:56:38 EST 2025 Thu Apr 03 06:59:49 EDT 2025 Tue Nov 18 21:27:18 EST 2025 Sat Nov 29 07:11:08 EST 2025 Wed Jan 22 16:26:10 EST 2025 Mon Nov 10 09:04:19 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | non-Hodgkin lymphoma explanatory factors health care cost health care resource use cancer survivors rituximab |
| Language | English |
| License | 2021 American Cancer Society. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5228-6e781587b5b6311f13dd3a9e40835228a9f8c390c3ecf42ffc32722be4f35e93 |
| Notes | We are grateful to all the survivors who participated in the survey, and we gratefully acknowledge Sabine Anthony (Clinical Research and Innovation Office, Cimiez Hospital, Nice University Hospital Center, University of Côte d'Azur, Nice, France) and Lilian Laborde (Paoli‐Calmettes Institute–Provence‐Alpes‐Côte d'Azur Data Processing Center, Marseille, France) for their involvement in the management of the survey. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-0351-6040 0000-0002-9357-6476 0000-0003-4102-7261 0000-0002-9541-8666 0000-0002-3714-9824 0000-0003-2190-3527 0000-0003-0195-4378 |
| OpenAccessLink | https://inserm.hal.science/inserm-04783473 |
| PMID | 34605020 |
| PQID | 2621217149 |
| PQPubID | 2045183 |
| PageCount | 10 |
| ParticipantIDs | hal_primary_oai_HAL_hal_03692839v1 proquest_miscellaneous_2579091375 proquest_journals_2621217149 pubmed_primary_34605020 crossref_citationtrail_10_1002_cncr_33938 crossref_primary_10_1002_cncr_33938 wiley_primary_10_1002_cncr_33938_CNCR33938 nii_cinii_1870020692704294912 |
| PublicationCentury | 2000 |
| PublicationDate | February 01, 2022 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: February 01, 2022 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2022 |
| Publisher | Wiley Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley – name: Wiley Subscription Services, Inc |
| References | 2021; 26 2012; 2012 2016; 19 2019; 20 2017; 14 2020; 61 2019; 98 2006; 47 2016; 54 2011; 96 2011; 52 2019; 29‐30 2019; 19 2007 2019; 125 2017; 18 2020; 167 2018; 23 2009; 27 2018; 59 2019; 145 2018; 14 2001; 20 e_1_2_8_28_1 e_1_2_8_29_1 e_1_2_8_24_1 e_1_2_8_26_1 e_1_2_8_27_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_20_1 e_1_2_8_21_1 e_1_2_8_22_1 e_1_2_8_23_1 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 Yvonne M (e_1_2_8_25_1) 2007 Boulat T (e_1_2_8_6_1) 2019; 29 e_1_2_8_10_1 e_1_2_8_11_1 e_1_2_8_12_1 |
| References_xml | – volume: 61 start-page: 75 year: 2020 end-page: 83 article-title: Costs associated with follicular lymphoma among individuals diagnosed with non‐Hodgkin lymphoma: a longitudinal analysis using SEER‐Medicare data publication-title: Leuk Lymphoma – volume: 14 start-page: 308 year: 2017 article-title: Economic burden for lung cancer survivors in urban China publication-title: Int J Environ Res Public Health – volume: 167 start-page: 378 year: 2020 end-page: 384 article-title: Financial burden of thyroid cancer in the United States: an estimate of economic and psychological hardship among thyroid cancer survivors publication-title: Surgery – volume: 14 start-page: 335 year: 2017 end-page: 346 article-title: The landscape of new drugs in lymphoma publication-title: Nat Rev Clin Oncol – volume: 19 start-page: 645 year: 2019 end-page: 661 article-title: Cost burden of diffuse large B‐cell lymphoma publication-title: Expert Rev Pharmacoecon Outcomes Res – volume: 27 start-page: 657 year: 2009 end-page: 679 article-title: Economic burden of follicular non‐Hodgkin's lymphoma publication-title: Pharmacoeconomics – volume: 23 start-page: 375 year: 2018 end-page: 381 article-title: Retrospective analysis of first‐line treatment for follicular lymphoma based on outcomes and medical economics publication-title: Int J Clin Oncol – volume: 96 start-page: 1136 year: 2011 end-page: 1143 article-title: Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high‐risk diffuse large B‐cell lymphoma for GELA publication-title: Haematologica – volume: 14 start-page: 2627 year: 2018 end-page: 2642 article-title: Economic burden of patients with diffuse large B‐cell and follicular lymphoma treated in the USA publication-title: Future Oncol – volume: 59 start-page: 1133 year: 2018 end-page: 1142 article-title: Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B‐cell lymphoma publication-title: Leuk Lymphoma – volume: 2012 year: 2012 article-title: Impact on medical cost, cumulative survival, and cost‐effectiveness of adding rituximab to first‐line chemotherapy for follicular lymphoma in elderly patients: an observational cohort study based on SEER‐Medicare publication-title: J Cancer Epidemiol – year: 2007 – volume: 145 start-page: 239 year: 2019 end-page: 249 article-title: Comparison of the financial burden of survivors of head and neck cancer with other cancer survivors publication-title: JAMA Otolaryngol Head Neck Surg – volume: 20 start-page: 461 year: 2001 end-page: 494 article-title: Estimating log models: to transform or not to transform? publication-title: J Health Econ – volume: 20 start-page: 2131 year: 2019 end-page: 2137 article-title: The economic burden of breast cancer survivors in Korea: a descriptive study using a 26‐month micro‐costing cohort approach publication-title: Asian Pac J Cancer Prev – volume: 54 start-page: 343 year: 2016 end-page: 349 article-title: Estimating the population benefits and costs of rituximab therapy in the United States from 1998 to 2013 using real‐world data publication-title: Med Care – volume: 18 start-page: 1076 year: 2017 end-page: 1088 article-title: Rituximab‐dose‐dense chemotherapy with or without high‐dose chemotherapy plus autologous stem‐cell transplantation in high‐risk diffuse large B‐cell lymphoma (DLCL04): final results of a multicentre, open‐label, randomised, controlled, phase 3 study publication-title: Lancet Oncol – volume: 47 start-page: 1535 year: 2006 end-page: 1544 article-title: Medical costs associated with non‐Hodgkin's lymphoma in the United States during the first two years of treatment publication-title: Leuk Lymphoma – volume: 29‐30 start-page: 576 year: 2019 end-page: 584 article-title: Principales évolutions de la mortalité par cause sur la période 2000‐2016 en France métropolitaine publication-title: Bull Epidémiol Hebd – volume: 19 start-page: 965 year: 2016 end-page: 972 article-title: Clinical and economic burden of peripheral T‐cell lymphoma in commercially insured patients in the United States: findings using real‐world claims data publication-title: J Med Econ – volume: 52 start-page: 2117 year: 2011 end-page: 2123 article-title: Economic impact of disease progression in follicular non‐Hodgkin lymphoma publication-title: Leuk Lymphoma – volume: 26 start-page: e817 year: 2021 end-page: e826 article-title: Real‐world characteristics, treatment patterns, health care resource use, and costs of patients with diffuse large B‐cell lymphoma in the U.S publication-title: Oncologist – volume: 98 start-page: 175 year: 2019 end-page: 183 article-title: Burden of illness of follicular lymphoma and marginal zone lymphoma publication-title: Ann Hematol – volume: 125 start-page: 2291 year: 2019 end-page: 2299 article-title: Long‐term fatigue in survivors of non‐Hodgkin lymphoma: the Lymphoma Study Association SIMONAL cross‐sectional study publication-title: Cancer – ident: e_1_2_8_28_1 doi: 10.1016/j.surg.2019.09.010 – volume-title: Choices in Methods for Economic Evaluation ident: e_1_2_8_23_1 – ident: e_1_2_8_29_1 doi: 10.1001/jamaoto.2018.3982 – ident: e_1_2_8_8_1 doi: 10.1080/13696998.2016.1187622 – ident: e_1_2_8_27_1 doi: 10.3390/ijerph14030308 – ident: e_1_2_8_5_1 doi: 10.1016/S1470-2045(17)30444-8 – ident: e_1_2_8_13_1 doi: 10.1080/10428190600573325 – volume-title: ATC classification system: structure and principles ident: e_1_2_8_22_1 – ident: e_1_2_8_15_1 doi: 10.1155/2012/978391 – ident: e_1_2_8_19_1 doi: 10.1007/s00277-018-3501-8 – ident: e_1_2_8_7_1 – ident: e_1_2_8_17_1 doi: 10.2217/fon-2018-0267 – ident: e_1_2_8_2_1 – ident: e_1_2_8_26_1 doi: 10.31557/APJCP.2019.20.7.2131 – ident: e_1_2_8_24_1 doi: 10.1016/S0167-6296(01)00086-8 – ident: e_1_2_8_14_1 doi: 10.1097/MLR.0000000000000486 – volume-title: Discrete Multivariate Analysis Theory and Practice year: 2007 ident: e_1_2_8_25_1 – ident: e_1_2_8_4_1 doi: 10.1038/nrclinonc.2016.205 – ident: e_1_2_8_10_1 doi: 10.1080/10428194.2019.1648804 – ident: e_1_2_8_12_1 doi: 10.1080/14737167.2019.1680288 – ident: e_1_2_8_11_1 doi: 10.2165/11314820-000000000-00000 – ident: e_1_2_8_16_1 doi: 10.3109/10428194.2011.592623 – ident: e_1_2_8_18_1 doi: 10.1007/s10147-017-1202-2 – ident: e_1_2_8_3_1 doi: 10.3324/haematol.2010.038109 – volume: 29 start-page: 576 year: 2019 ident: e_1_2_8_6_1 article-title: Principales évolutions de la mortalité par cause sur la période 2000‐2016 en France métropolitaine publication-title: Bull Epidémiol Hebd – ident: e_1_2_8_21_1 doi: 10.1002/cncr.32040 – ident: e_1_2_8_20_1 doi: 10.1002/onco.13721 – ident: e_1_2_8_9_1 doi: 10.1080/10428194.2017.1375100 |
| SSID | ssib002667593 ssib058492470 ssib020716606 ssib053388019 ssib002667594 ssib000462005 ssib000180361 ssib002399320 ssib000080738 ssib001235839 ssib001228660 ssib000235543 ssib005594604 ssj0007253 ssib006673822 ssib001235842 ssib005900681 ssib050995393 ssib000515426 ssib002399617 |
| Score | 2.3939478 |
| Snippet | Background
No study has focused on the economic burden in non‐Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on... Improvements in the management of non‐Hodgkin lymphoma (NHL) have led to longer survival with potentially increased health care consumption and costs. This... No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care... BackgroundNo study has focused on the economic burden in non‐Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on... |
| SourceID | hal proquest pubmed crossref wiley nii |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 519 |
| SubjectTerms | [INFO.INFO-CR]Computer Science [cs]/Cryptography and Security [cs.CR] [INFO.INFO-DC]Computer Science [cs]/Distributed [INFO.INFO-DC]Computer Science [cs]/Distributed, Parallel, and Cluster Computing [cs.DC] [INFO.INFO-ET]Computer Science [cs]/Emerging Technologies [cs.ET] [INFO.INFO-IU]Computer Science [cs]/Ubiquitous Computing [INFO.INFO-MA]Computer Science [cs]/Multiagent Systems [cs.MA] [INFO.INFO-MO]Computer Science [cs]/Modeling and Simulation [INFO.INFO-SE]Computer Science [cs]/Software Engineering [cs.SE] and Cluster Computing [cs.DC] Autografts cancer survivors Computer Science Cost analysis Costs Cross-Sectional Studies Cryptography and Security Distributed, Parallel, and Cluster Computing Economics Emerging Technologies explanatory factors Financial Stress health care cost Health Care Costs Health care expenditures health care resource use Hematopoietic Stem Cell Transplantation Humans Immunotherapy Lymphoma Lymphoma, Non-Hodgkin Lymphoma, Non-Hodgkin - therapy Missing data Modeling and Simulation Monoclonal antibodies Multiagent Systems Non-Hodgkin's lymphoma non‐Hodgkin lymphoma Oncology Parallel Retrospective Studies Rituximab Sensitivity analysis Software Engineering Statistical analysis Stem cell transplantation Stem cells Survival Survivors Targeted cancer therapy Transplantation Transplantation, Autologous Ubiquitous Computing |
| Title | Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study |
| URI | https://cir.nii.ac.jp/crid/1870020692704294912 https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.33938 https://www.ncbi.nlm.nih.gov/pubmed/34605020 https://www.proquest.com/docview/2621217149 https://www.proquest.com/docview/2579091375 https://hal.science/hal-03692839 |
| Volume | 128 |
| WOSCitedRecordID | wos000703020300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1097-0142 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0142 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007253 issn: 0008-543X databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFD5aO4R44X4JbJO5vIAU1thxbSNepkLVSV2FxoC-RY7jsIqRoGatNJ74CfxGfgnHzmVMmpAQL1ESnySOz8WfbJ_PAM-s5WrAZRpGqYzcaFUeppLZkEdWCsNsbHx69MepmM3kfK7ebcDrNhem5ofoBtycZ_h47Rxcp9XuOWmoKczyJWOKyR5sUjRc3ofNN4fjD9MuEgvasFAOZMhjNu_oSenu-dMXOqTesVsO2SsWi8sQ50UA63ug8Y3_q_tNuN4gT7JXm8ot2LDFbbh60Myt34HvbY4ySX1qA1kUpCiLXz9-Tsrs8xe8OjlD1ZdfNalWGGDW5bJ6RdDMyNhlDB6TaVvs1iaekT8UT97vHzjKXeKbAN9Y-QVgrjqe3vYuHI3fHo0mYbMzQ2gQr8lwaIWMuBQpT4csivKIZRnTysY1oJNa5dIwNUBlmzymeW4YFZSmNs4Zt4rdgz7-gH0AJBtqKxDnaaV0rIe5zg3HmGDjzO2UNYgDeN5qJzENa7nbPOMkqfmWaeLaMvFtGcDTTvZbzdVxqdQTVHIn4Oi1J3vTxN3D3lwh3FLrKIBttAH8ojtGGNMQVWOZcN13rCIawFZrHUnj9FVCh4gD3IbyKoDHXTG6q5uD0YUtVyjDhXJUrIIHcL-2qq4qzM1R44cCeOGN5y8_kYxmo0N_9vBfhB_BNerSN_yq8y3ony5XdhuumPXpolruQE_M5U7jRHj1aX_2GxZ-Hao |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB7RBQEX3o_ALpjHBaSwdZyHzW1VUbUijRBU0FuUOA5bsSSo2VZaTvwEfiO_hBknzbLSCglxqdJ60jiehz_ZM58BnhsTqGEgc5fnktNqVenmUhg34EZGWhhf2_Loj3GUJHKxUO-63ByqhWn5IfoFN_IMG6_JwWlBev-UNVRXevVKCCXkAC76iDTo5IZP06QPxJHXkVAOpRv4YtGzk3r7p_eemY8Gh5QNOaiWy_MA51n8aieg8fX_7PoNuNYhT3bQmspNuGCqW3B51u2t34bv2xplltvSBrasWFVXv378nNTF5y_47egEVV9_zVizxgCzqVfNa4ZmxsZUMXjI4m0z5SaesD8Uzz5MZ0S5y-wY4D82NgGMumPpbe_AfPxmPpq43ckMrka8Jt3QRJIHMsqDPBScl1wUhciU8VtAJzNVSi3UEJWtS98rSy28yPNy45ciMErchR18AXMfWBFmJkKclymV-VlYZqUOMCYYv6CTsoa-Ay-26kl1x1pOh2ccpS3fspfSWKZ2LB141st-a7k6zpV6ilruBYhee3IQp_QbzuYK4ZbacAf20AjwifTJMaYhqsa2iKZvX3HPgd2teaSd0zepFyIOoAPllQNP-mZ0V9qDySpTr1EmiBRRsUaBA_das-q7ImiPGh_kwEtrPX95iXSUjN7bqwf_IvwYrkzmsziNp8nbh3DVo1IOm4G-CzvHq7XZg0t6c7xsVo-sJ_0GK_kedQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB6RFFW98H4YWlgeF5BMY68fu9yqlCgVblSVgnKz7PVuG1HsKm4ilRM_gd_IL2Fm7bhUqpAQFyvOTuL1zszup92ZbwBeax3KQShy18uFR7tVxs0F127oaRErrgNl06O_JPFkIqZTedDG5lAuTMMP0W24kWfY-ZocXJ8VZvuSNVSVav6Oc8lFD9YCqiLTh7Xdw9HnpJuKY7-loRwINwz4tOMn9bcvf31lReqdUDxkr5zNroOcVxGsXYJGt_-z83fgVos92U5jLHfhhi7vwfp-e7p-H76vspRZbpMb2KxkZVX--vFzXBXHX_Hu9AKVX33LWL3AKWZZzev3DA2NjShn8IQlq2aKTrxgf6iefdrbJ9JdZscA_7G2IWDUHUtw-wCORh-OhmO3rc3gKkRswo10LLxQxHmYR9zzjMeLgmdSBw2kE5k0QnE5QHUrE_jGKO7Hvp_rwPBQS_4Q-vgC-jGwIsp0jEgvkzILsshkRqEu0UoKqpU1CBx4s1JPqlreciqfcZo2jMt-SmOZ2rF04FUne9awdVwr9RK13AkQwfZ4J0npO1zPJQIuufQc2EIjwCfS1cNZDXE1tsW0gAfS8x3YXJlH2rp9nfoRIgEqKS8deNE1o8PSKUxW6mqBMmEsiYw1Dh141JhV1xVOp9T4IAfeWuv5y0ukw8nw0H568i_Cz2H9YHeUJnuTj09hw6dcDhuCvgn98_lCb8FNtTyf1fNnrSv9BhMNHx4 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Economic+burden+in+non-Hodgkin+lymphoma+survivors%3A+The+French+Lymphoma+Study+Association+SIMONAL+cross-sectional+study&rft.jtitle=Cancer&rft.au=Nerich%2C+Virginie&rft.au=Guyeux%2C+Christophe&rft.au=Henry-Amar%2C+Michel&rft.au=Couturier%2C+Rapha%C3%ABl&rft.date=2022-02-01&rft.eissn=1097-0142&rft.volume=128&rft.issue=3&rft.spage=519&rft_id=info:doi/10.1002%2Fcncr.33938&rft_id=info%3Apmid%2F34605020&rft.externalDocID=34605020 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |